Paul J. Mitchell Sells 1,000 Shares of Alkermes PLC (ALKS) Stock

Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of Alkermes stock in a transaction on Friday, December 1st. The shares were sold at an average price of $51.98, for a total value of $51,980.00. Following the completion of the sale, the director now owns 9,000 shares in the company, valued at approximately $467,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alkermes PLC (NASDAQ:ALKS) traded up $1.41 during trading hours on Friday, hitting $53.70. The stock had a trading volume of 1,686,908 shares, compared to its average volume of 902,468. Alkermes PLC has a twelve month low of $46.42 and a twelve month high of $63.40. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The business had revenue of $217.40 million during the quarter, compared to analysts’ expectations of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.09) EPS. research analysts forecast that Alkermes PLC will post -0.59 earnings per share for the current year.

ALKS has been the topic of several research analyst reports. UBS set a $54.00 price objective on Alkermes and gave the company a “hold” rating in a report on Friday, October 27th. Mizuho set a $81.00 price objective on Alkermes and gave the company a “buy” rating in a report on Saturday, October 21st. Credit Suisse Group set a $66.00 price objective on Alkermes and gave the company a “buy” rating in a report on Tuesday, November 28th. Citigroup set a $62.00 price objective on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. Finally, Jefferies Group set a $69.00 price objective on Alkermes and gave the company a “buy” rating in a report on Friday, August 25th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $63.55.

Several large investors have recently added to or reduced their stakes in ALKS. Dimensional Fund Advisors LP boosted its position in shares of Alkermes by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 194,531 shares of the company’s stock worth $11,381,000 after acquiring an additional 2,891 shares in the last quarter. Capstone Asset Management Co. boosted its position in shares of Alkermes by 2.6% in the 2nd quarter. Capstone Asset Management Co. now owns 6,755 shares of the company’s stock valued at $392,000 after purchasing an additional 170 shares during the period. Aperio Group LLC boosted its position in shares of Alkermes by 3.2% in the 2nd quarter. Aperio Group LLC now owns 25,440 shares of the company’s stock valued at $1,475,000 after purchasing an additional 782 shares during the period. US Bancorp DE boosted its position in shares of Alkermes by 366.4% in the 2nd quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after purchasing an additional 3,122 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Alkermes in the 2nd quarter valued at about $554,000. 99.75% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/03/paul-j-mitchell-sells-1000-shares-of-alkermes-plc-alks-stock.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

What are top analysts saying about Alkermes PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit